88 results about "Immune Cell Function" patented technology

The invention relates to the technical field of database construction, in particular to a construction method and system for a reproductive medicine database. The method comprises the following steps: acquiring a biological tissue sample of a patient; acquiring reproductive endocrine hormone data, embryo morphological parameter data, immune cell function data and genome variation data from the biological tissue sample of the patient; performing time sequence analysis processing on the hormone fluctuation mode according to the reproductive endocrine hormone data to obtain endocrine dynamic characteristic data; performing image recognition processing based on coherent superposition characteristics of light on the embryo morphological parameter data, and performing embryo development potential evaluation to obtain embryo development potential data; and performing hierarchical clustering processing on the individual heterogeneity of the patient according to the immune cell function data and the genome variation data to obtain immune-genetic typing data of the patient. By means of the quantum dot sensing technology and the multi-channel micro-fluidic chip, standardization of data acquisition is achieved, and the heterogeneity problem of a data source is solved.

The invention relates to a novel CD8 < + > original T cell subgroup and application thereof. The invention discloses a brand new separated cell population, namely an immune cell population which takes whether CCL5 is expressed or not as a marker, namely a CCL5 + CD8 + # imgabs0 # T cell population or a CCL5-CD8 + # imgabs1 # T cell population (# imgabs2 # (TSN) subpopulation). Wherein the CCL5 + CD8 + # imgabs3 # T cell population can be used as an analysis target and is used for analyzing functions of immune cells. The invention also provides a method for sorting the cells and the like. The invention provides a new way for application research and clinical regulation of immune cells.

The invention relates to the technical field of biological medicines, in particular to FcRL2 as a serum marker or cerebrospinal fluid marker for early diagnosis, screening and typing detection of neurosyphilis patients. The FcRL2 protein is one of receptor superfamily members, Fc receptor-like glycoproteins, and is related to immune response regulation and immune cell functions. According to the invention, the concentration of the FcRL2 protein in serum or cerebrospinal fluid is used as an index for early diagnosis of neurosyphilis, typing detection of symptomatic neurosyphilis, asymptomatic neurosyphilis, neurosyphilis and recessive syphilis, evaluation of nerve injury degree and the like; the index can be independently used or used as a main reference index to be combined with other indexes to complete diagnosis screening, typing and nerve injury evaluation of the neurosyphilis. Compared with the prior art, the FcRL2 not only has high sensitivity, but also can diagnose the neurosyphilis through noninvasive serum detection, and is beneficial to diagnosis and management of the neurosyphilis in community hospitals and local hospitals.

Provided herein are anti-CD8 antigen binding molecules and fusion polypeptides comprising the CD8 antigen binding molecules for selectively modulating the function of CD8+ T cells over other immune cells. In addition, the present disclosure also provides polynucleotides encoding the disclosed antigen binding molecules and fusion polypeptides, and vectors and host cells comprising such polynucleotides. The present disclosure further provides methods for producing the antigen binding molecules and fusion polypeptides, pharmaceutical compositions comprising the same, and uses thereof.

The present invention provides, in some embodiments, methods of promoting an immune response in a subject in need thereof, comprising administering to the subject a population of immune cells that express an enzyme that facilitates immune cell function in a nutrient-poor environment. The invention also provides, in other embodiments, compositions comprising an ex vivo population of immune cells expressing an enzyme that enhances immune cell function in a nutrient-poor environment.

An object of the present invention is to provide a method for preventing or treating myopia, and a composition used in said method. The present invention provides a method and composition for inhibiting, improving, or treating myopia by administering a substance that induces M2 macrophage polarization, a substance that regulates the function of choroid-resident immune cells, such as a mast cell stabilizer or a chemical mediator release inhibitor, or lactic acid bacteria. Regulating the function of choroid-resident immune cells, for example by inducing the polarization of M2 macrophages in the choroid or by administering a mast cell stabilizer, a chemical mediator release inhibitor, or lactic acid bacteria, is effective in myopia prevention and treatment.

This disclosure describes an artificial expression construct containing a PD1:cytokine chimeric transgene under the control of an inducible promoter. The artificial expression construct of this disclosure can be used to enhance the function of immune cells (e.g., CAR-T cells) that have recombinant receptors. The inducible PD1:cytokine chimeric transgene disclosed herein enhances the potency of immune cells (e.g., CAR-T cells) that have recombinant receptors, thereby enhancing killing, proliferation of immune cells, and / or cytokine production.

Fusion proteins that bind to human CD8α, human CDSβ, or human PD1 and comprise mutant IL-2 polypeptides, as well as polynucleotides, host cells, compositions, and methods of use thereof, are provided herein. The present disclosure describes, inter alia, mutant IL-2 polypeptides having one, two, or more, or three, or more amino acid substitutions (i.e., mutations) relative to the wild-type mature IL-2 amino acid sequence, e.g., as depicted in Figure 1A (SEQ ID NO: 1) and Figure 2.

The invention provides an immune senescence detection marker Granzyme B, an immune senescence regulation and control target BHLHE40 and application, and belongs to the technical field of biological medicine. The invention discloses the continuous up-regulation characteristic of the GZMB in the senescence process of the primate immune system for the first time, defines the consistent expression trend of the GZMB in various immune tissues, and determines that the GZMB can be used as a reliable molecular marker for reflecting the overall immune senescence state. The invention also discloses a key regulatory pathway for immune aging, and finds that the GZMB can activate an NF-kappa B signal pathway, up-regulate inflammation and aging related genes such as CDKN1A, NFKBIA and S100A4, and promote functional degradation of immune cells; it is identified that the transcription factor BHLHE40 is a key upstream regulation factor of GZMB, expression of GZMB and downstream senescence genes can be remarkably reduced by knocking down BHLHE40, and the core effect of the BHLHE40-GZMB pathway in immune senescence is clarified.

The invention belongs to the technical field of biological medicines, and particularly discloses application of aspirin in enhancing the curative effect of tumor infiltrating lymphocyte on treating liver cancer. The invention discloses application of aspirin in preparation of a medicine for enhancing the curative effect of tumor infiltrating lymphocyte on hepatocellular carcinoma. The invention discloses an application of aspirin in enhancing the curative effect of tumor infiltrating lymphocyte on treating liver cancer, the aspirin overcomes the problem of drug resistance of TIL therapy in HCC by adjusting the immune cell function in a tumor microenvironment, and the treatment effect is improved.

The invention discloses a broncholung lavage fluid composition for treating non-small cell lung cancer, and relates to the technical field of cancer treatment. The preparation method of the bronchus lung lavage fluid composition for treating the non-small cell lung cancer comprises the following steps: S1, performing metagenome sequencing on a BALF sample, S2, grouping by R / NR based on differential strains obtained in S1 to obtain core bacteria, performing single-strain Kaplan-Meier survival analysis on the strains, and determining the survival rate of the single-strain Kaplan-Meier to obtain the bronchus lung lavage fluid composition for treating the non-small cell lung cancer. Finally, seven key microorganisms, namely bronchopulmonary lavage fluid combinations, which are remarkably related to immunotherapy PFS are locked; s3, determining the relationship between the seven key BALF bacteria and the existing immune therapeutic effect marker; and S4, verifying the generation conditions of IL6, IL8 and RANTES cytokines promoted by the seven strains through an in-vitro cell experiment, and revealing the activation and enhancement effects of the seven strains on immune cell functions. According to the invention, the immunotherapy effect of the non-small cell lung cancer patient can be promoted to be improved by combining a plurality of beneficial specific microorganisms in an airway administration mode. In conclusion, the method has a good application prospect.

The present disclosure relates to the field of cell therapy, and more specifically, to improving CAR and / or TCR function through improvement of cytokine signaling. Disclosed are embodiments of a membrane bound interleukin 15 (IL-15)-IL-15Ralpha sushi domain chimeric receptor. The chimeric receptor may comprise a FAS transmembrane domain or an IL-7 transmembrane domain. Different embodiments of the chimeric receptor have different polypeptide lengths between the IL-15 region and the transmembrane domain.

Artificial expression constructs including a dnSHP1, caBCL2, dnNRDP1, PCK1, cFLIP.v3, caAKT, survivin, or dnFADD transgene under the control of an inducible promoter are described. The artificial expression constructs can be used to enhance the function of a recombinant receptor-immune cell (e.g., CAR T-cell). The dnSHP1, caBCL2, dnNRDP1, PCK1, cFLIP.v3, caAKT, survivin, or dnFADD transgene disclosed herein enhances the potency of the recombinant receptor-immune cell (e.g., CAR T-cell), resulting in potentiated cell killing ability, proliferation, cytokine output, and / or maintenance of artificial expression construct positivity.

The invention specifically discloses a composition for immunotherapy of bile duct cancer and application thereof, and relates to the technical field of biological medicines. The invention provides a pharmaceutical composition. The pharmaceutical composition comprises: (1) a therapeutically effective amount of an immune checkpoint inhibitor and a CD151 antibody; and (2) a pharmaceutically or immunologically acceptable carrier or excipient. By targeting the membrane protein CD151 of tumor-associated fibroblasts, the cGAS-sting mediated I-type IFN reaction is activated, the innate immunity of the cells is enhanced, and more CD8 + T cells are activated and recruited. The combined use of the CD 151 targeted inhibitor and the PD-1 immune checkpoint inhibitor can enhance the problems of less immune cell infiltration, low function and the like of immunotherapy in bile duct cancer, solves the problems of poor effect, immune escape and insufficient immune cell function of existing immunotherapy, and finally improves the treatment effect of bile duct cancer and patient prognosis.

The application discloses a bispecific chimeric antigen receptor targeting HER2 and HLA-G and application thereof, and belongs to the tumor immunotherapy field.The chimeric antigen receptor comprises an extracellular domain, a hinge domain, a transmembrane domain and at least one intracellular domain, and the extracellular domain comprises an anti-HER2 single-chain antibody and an anti-HLA-G single-chain antibody.The bispecific chimeric antigen receptor of the application can effectively improve the killing signal of immune cells, and can effectively avoid the inhibition of the immunosuppressive signal on the function of immune cells, thereby delaying the recurrence of tumors, and has very important clinical application value.

The present disclosure relates to methods for generating immune cells with enhanced functions. More specifically, disclosed herein is a method for enhancing immune cell function, which includes modifying immune cells to inhibit the function of at least one gene selected from the group consisting of RC3H1, RC3H2, A2AR, FAS, TGFBR1, and TGFBR2. Also disclosed herein is a method that includes modifying stem cells or progenitor cells capable of differentiating into immune cells to inhibit the function of at least one gene selected from the group consisting of RC3H1, RC3H2, A2AR, FAS, TGFBR1, and TGFBR2. Also disclosed are immune cells or stem cells prepared by the methods of the present invention and the use of immune cells in therapeutic treatment.

The present application relates to the technical field of biological medicine, and particularly relates to application of fullerenol in preparation of tumor prevention or treatment drugs for inducing trained immunity. The present application finds that fullerenol can induce formation of trained immunity, activate immune reprogramming of bone marrow hematopoietic stem cells, produce long-term pro-inflammatory phenotype, form persistent immune memory, and further enhance functions of innate immune cells. It is verified by experiments that fullerenol can significantly inhibit tumor growth in an animal model without obvious systemic toxicity; epigenetic remodeling of bone marrow hematopoietic stem cells can be sustained for several weeks to several months, and has long-acting anti-recurrence potential. In addition, trained immunity induced by fullerenol can be used for immune regulation of various solid tumors, and fullerenol is simple in synthesis, can be produced on a large scale, has excellent biocompatibility and stability. Therefore, the present application has wide application prospect.

In aspects, a chimeric cytokine receptor (CCR) is provided that comprises (i) a single chain variable fragment (scFv) which specifically binds to an antigen, one or more extracellular interleukin receptor domains, an interleukin receptor transmembrane domain, and an interleukin receptor intracellular domain; and (ii) a single chain variable fragment (scFv) which specifically binds to an antigen, one or more extracellular interleukin receptor common gamma chain (γc) domains, a γc transmembrane domain, and a γc intracellular domain.

The invention provides an oral liquid based on algal oil-curcumin synergistic anti-inflammation and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The oral liquid comprises the following raw materials: an anti-inflammatory agent (consisting of algae oil and curcumin), a traditional Chinese medicine extract (consisting of a herba houttuyniae extract and an Indian kalimeris herb extract), phospholipid, fructo-oligosaccharide, an antioxidant, a stabilizer (consisting of Arabic gum and hydroxypropyl-beta-cyclodextrin) and a flavoring agent. Experimental results show that the anti-inflammatory oral liquid is high in stability, and the content of inflammatory factors in mice with LPS-induced chronic inflammation can be remarkably reduced. The oral liquid can relieve chronic inflammation symptoms by regulating immune cell functions, blocking inflammation signal channels and other multi-target mechanisms, is high in safety after being used for a long time, does not have obvious adverse reaction, and provides a new choice for clinical treatment of chronic inflammatory diseases.

Provided herein are methods of modifying immune cell activity by altering KJR2DL5 expression and / or activity. The methods, which include administering to a subject one or more agents that decrease KJR2DL5 expression and / or activity, increase immune cell function, and treat diseases such as cancer and infectious diseases.

The invention relates to a piezoelectric nano-material with ultrasonic responsiveness, which is a PVP (Polyvinyl Pyrrolidone) modified bismuth oxyiodate nano-sheet, the particle size is 100-200 nm, and a surface electric field can be generated under the ultrasonic action. The piezoelectric nano material can hyperpolarize the potential of a T cell membrane and inhibit an ion channel Kv1.3 regulated and controlled by the membrane potential, so that Th17 cell differentiation is reduced, and joint inflammation is relieved; the piezoelectric nano material is further prepared into a joint injection preparation, and the joint injection preparation can be combined with ultrasonic irradiation to be applied to treatment of rheumatoid arthritis. According to the invention, the piezoelectric nano material is successfully applied to immune microenvironment regulation and control of rheumatoid arthritis for the first time, and the product and technology blank in the field of'precisely regulating and controlling immune cell functions by using physical signals to treat autoimmune diseases' is filled.

The methods and compositions disclosed herein relate to the field of cell therapy, and more specifically, to improving CAR and / or TCR function through improvement of the tumor microenvironment via improvement in cytokine signaling. Methods of treating a cancer in a patient are disclosed comprising administering to the patient immune cells expressing a chimeric antigen receptor or T-cell receptor and a membrane bound IL-18. Further disclosed are nucleic acids which encode a membrane bound IL-18 and methods for culturing cells expressing such nucleic acids.

The use of piceatannol as an immune function enhancer in tumor immunotherapy, which use belongs to the technical field of biomedicine. Piceatannol can regulate the ratio and function of immune cells such as T cells, B cells, macrophages, neutrophils, monocytes and myeloid-derived suppressor cells, thereby improving an immune microenvironment in the body, remodeling a tumor immune microenvironment by means of inhibiting the migration of immunosuppressive cells to tumors, and inhibiting the growth and metastasis of melanoma, colorectal cancer and breast cancer. Piceatannol has application prospects in the treatment and prevention of various cancers. It is suggested that piceatannol can significantly improve the effects on anti-tumor immune responses and remodel the tumor immune microenvironment, thereby effectively inhibiting tumor proliferation, growth and metastasis, and can be used for the preparation of a drug for regulating immune cell functions or can be used as a lead compound for the development of a tumor immunotherapeutic drug.

The application relates to modified immune effector cells with enhanced immune cell function, as well as related pharmaceutical compositions. The application further relates to methods for generating the modified immune effector cell and methods for using the modified immune effector cell for treatment of diseases (e g., adoptive cell therapy).

The invention relates to an application of a CXCL13 + CD8 + T cell subset in preparation of a product for predicting prognosis of a melanoma patient, and the CXCL13 + CD8 + T cell subset is used as an analysis target to prepare a reagent for analyzing immune cell functions. Wherein the CXCL13 < + > CD8 < + > T cell subset refers to a CD8 < + > T cell subset capable of releasing a CXCL13 signal. Compared with the prior art, the research shows that by analyzing the expression level of effector molecules and immune checkpoint molecules in a tumor microenvironment and the density of a three-level lymph structure, the prognosis of a tumor patient can be more accurately predicted, and the reactivity of tumors to immunotherapy can be predicted; at present, a report for reflecting immune characteristics of melanoma by using the CXCL13 + CD8 + T cell subset as a biomarker is not found. The infiltration level of CXCL13 + CD8 + T cells in tumor tissues is quantitatively evaluated through flow cytometry, and more accurate and sensitive indexes are provided for prognosis evaluation of melanoma and liver cancer patients.

The present disclosure provides polypeptide constructs that, when exposed to sufficient levels of ATP, cause them to assemble into dimers or higher order complexes (e.g., trimers, tetramers, etc.), thereby acting as immune cell function agonists. The constructs can also be conjugated to one or more therapeutic, chemotherapeutic, or labeling agents. The complexes of the constructs are capable of stimulating immune cells (e.g., cytotoxic CD8+ T cells and / or NK cells) that function to promote an anti-tumor immune response, and delivering the conjugated agent to the tumor microenvironment. The constructs can be used as anti-cancer / therapeutic agents for the treatment of solid tumors with elevated ATP levels.

The application provides modified immune effector cells with enhanced immune cell functions (e.g., enhanced anti-tumor effects), as well as related pharmaceutical compositions. The application further provides methods for generating the modified immune effector cells and methods for using the modified immune effector cells for treatment of diseases (e.g., adoptive cell therapy).

The present application relates to the technical field of database construction, and particularly relates to a method and system for constructing a reproductive medicine database. The method comprises the following steps: obtaining a patient biological tissue sample; obtaining reproductive endocrine hormone data, embryo morphology parameter data, immune cell function data and genomic variation data of the patient biological tissue sample; performing time series analysis and processing on hormone fluctuation patterns according to the reproductive endocrine hormone data to obtain endocrine dynamic characteristic data; performing image recognition processing based on light coherence superposition characteristics on the embryo morphology parameter data, and performing embryo development potential evaluation to obtain embryo development potential data; and performing hierarchical clustering processing on patient individual heterogeneity according to the immune cell function data and the genomic variation data to obtain patient immune-heredity typing data. The present application realizes standardization of data acquisition through quantum dot sensing technology and a multi-channel microfluidic chip, and solves the problem of heterogeneity of data sources.

This invention provides a method for generating immune cells with enhanced function. [Solution] A method for enhancing the function of immune cells is disclosed herein, comprising modifying immune cells to inhibit the function of at least one gene selected from the group consisting of RC3H1, RC3H2, A2AR, FAS, TGFBR1, and TGFBR2. A method also disclosed herein, comprising modifying stem cells or progenitor cells that can differentiate into immune cells to inhibit the function of at least one gene selected from the group consisting of RC3H1, RC3H2, A2AR, FAS, TGFBR1, and TGFBR2. The use of immune cells or stem cells produced by this method, and immune cells in therapeutic treatments, is also disclosed herein.

In aspects, a chimeric cytokine receptor (CCR) is provided that comprises (i) a single chain variable fragment (scFv) which specifically binds to an antigen, one or more extracellular interleukin receptor domains, an interleukin receptor transmembrane domain, and an interleukin receptor intracellular domain; and (ii) a single chain variable fragment (scFv) which specifically binds to an antigen, one or more extracellular interleukin receptor common gamma chain (γc) domains, a γc transmembrane domain, and a γc intracellular domain.